Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alfonso Quintás-Cardama

Showing results (1-10 of 131) with videos related to

Pageof 14
Sort By:
Molecular Cancer Therapeutics|March 3, 2019
What CAR Will Win the CD19 Race?Alfonso Quintás-Cardama
Leukemia Research|January 15, 2013
The role of Janus kinase 2 (JAK2) in myeloproliferative neoplasms: therapeutic implicationsAlfonso Quintás-Cardama
Cancer|July 19, 2011
Spleen deflation and beyond: the pros and cons of Janus kinase 2 inhibitor therapy for patients with myeloproliferative neoplasmsAlfonso Quintás-Cardama, Srdan Verstovsek
Targeted Oncology|April 4, 2009
Targeted therapy for chronic lymphocytic leukemiaAlfonso Quintás-Cardama, Susan O'Brien
Expert Opinion on Investigational Drugs|June 14, 2008
Therapeutic options for patients with clonal and idiopathic hypereosinophiaAlfonso Quintás-Cardama, Jorge Cortes
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 15, 2013
Molecular pathways: Jak/STAT pathway: mutations, inhibitors, and resistanceAlfonso Quintás-Cardama, Srdan Verstovsek
Future Oncology (London, England)|October 17, 2008
Nilotinib: a phenylamino-pyrimidine derivative with activity against BCR-ABL, KIT and PDGFR kinasesAlfonso Quintás-Cardama, Jorge Cortes
Leukemia Research|February 5, 2008
Tailoring tyrosine kinase inhibitor therapy to tackle specific BCR-ABL1 mutant clonesAlfonso Quintás-Cardama, Jorge Cortes
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 17, 2008
Therapeutic options against BCR-ABL1 T315I-positive chronic myelogenous leukemiaAlfonso Quintás-Cardama, Jorge Cortes
Blood|October 2, 2008
Molecular biology of bcr-abl1-positive chronic myeloid leukemiaAlfonso Quintás-Cardama, Jorge Cortes
Pageof 14

Showing results (1-10 of 131) with videos related to

Sort By:
Pageof 14
Molecular Cancer Therapeutics|March 3, 2019
What CAR Will Win the CD19 Race?Alfonso Quintás-Cardama
Leukemia Research|January 15, 2013
The role of Janus kinase 2 (JAK2) in myeloproliferative neoplasms: therapeutic implicationsAlfonso Quintás-Cardama
Cancer|July 19, 2011
Spleen deflation and beyond: the pros and cons of Janus kinase 2 inhibitor therapy for patients with myeloproliferative neoplasmsAlfonso Quintás-Cardama, Srdan Verstovsek
Targeted Oncology|April 4, 2009
Targeted therapy for chronic lymphocytic leukemiaAlfonso Quintás-Cardama, Susan O'Brien
Expert Opinion on Investigational Drugs|June 14, 2008
Therapeutic options for patients with clonal and idiopathic hypereosinophiaAlfonso Quintás-Cardama, Jorge Cortes
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 15, 2013
Molecular pathways: Jak/STAT pathway: mutations, inhibitors, and resistanceAlfonso Quintás-Cardama, Srdan Verstovsek
Future Oncology (London, England)|October 17, 2008
Nilotinib: a phenylamino-pyrimidine derivative with activity against BCR-ABL, KIT and PDGFR kinasesAlfonso Quintás-Cardama, Jorge Cortes
Leukemia Research|February 5, 2008
Tailoring tyrosine kinase inhibitor therapy to tackle specific BCR-ABL1 mutant clonesAlfonso Quintás-Cardama, Jorge Cortes
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 17, 2008
Therapeutic options against BCR-ABL1 T315I-positive chronic myelogenous leukemiaAlfonso Quintás-Cardama, Jorge Cortes
Blood|October 2, 2008
Molecular biology of bcr-abl1-positive chronic myeloid leukemiaAlfonso Quintás-Cardama, Jorge Cortes
Pageof 14